Австралия - английский - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - dibasic sodium phosphate, quantity: 4.3 g; monobasic sodium phosphate, quantity: 18.8 g - oral liquid - excipient ingredients: glycerol; saccharin sodium; sodium benzoate; purified water; flavour - for use as part of a bowel cleansing regimen in preparing adult patients for colon surgery or for preparing the colon for x-ray or endoscopic examination.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - levetiracetam, quantity: 100 mg/ml - oral liquid, solution - excipient ingredients: maltitol solution; purified water; citric acid monohydrate; glycerol; methyl hydroxybenzoate; propylene glycol; sodium citrate dihydrate; acesulfame potassium; propyl hydroxybenzoate; ammonium glycyrrhizinate; flavour - use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation; monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy; add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme); and add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

Австралия - английский - Department of Health (Therapeutic Goods Administration)

a menarini australia pty ltd - nitisinone, quantity: 4 mg - oral liquid, suspension - excipient ingredients: hypromellose; glycerol; polysorbate 80; sodium benzoate; citric acid monohydrate; sodium citrate; purified water; flavour - orfadin (nitisinone) is indicated for the treatment of patients with hereditary tyrosinaemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - lansoprazole, quantity: 30 mg - tablet, orally disintegrating - excipient ingredients: hyprolose; iron oxide yellow; magnesium stearate; magnesium carbonate hydrate; polysorbate 80; microcrystalline cellulose; mannitol; iron oxide red; purified water; crospovidone; titanium dioxide; hypromellose; polyacrylate dispersion (30 per cent); purified talc; glyceryl monostearate; triethyl citrate; aspartame; methacrylic acid - ethyl acrylate copolymer (1:1); citric acid; macrogol 6000; flavour; xylitol; calcium hydrogen phosphate - adults:,1.healing and long-term management of reflux oesophagitis.,2.healing and long-term management for patients with duodenal ulcer.,3.healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.,4.lansoprazole is also effective in patients with benign peptic lesions that do not respond to h2-receptor antagonists.,5.eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics (see clinical trials).,6.relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia.,paediatric patients 6 to 17 years of age.,1.treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis.,2.healing of erosive oesophagitis.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - lansoprazole, quantity: 15 mg - tablet, orally disintegrating - excipient ingredients: mannitol; citric acid; hypromellose; aspartame; microcrystalline cellulose; methacrylic acid - ethyl acrylate copolymer (1:1); titanium dioxide; iron oxide yellow; triethyl citrate; purified talc; purified water; magnesium carbonate hydrate; polysorbate 80; hyprolose; polyacrylate dispersion (30 per cent); magnesium stearate; glyceryl monostearate; crospovidone; iron oxide red; macrogol 6000; xylitol; calcium hydrogen phosphate; flavour - adults:,1.healing and long-term management of reflux oesophagitis.,2.healing and long-term management for patients with duodenal ulcer.,3.healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.,4.lansoprazole is also effective in patients with benign peptic lesions that do not respond to h2-receptor antagonists.,5.eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics (see clinical trials).,6.relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia.,paediatric patients 6 to 17 years of age.,1.treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis.,2.healing of erosive oesophagitis.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - lansoprazole, quantity: 30 mg - tablet, orally disintegrating - excipient ingredients: purified talc; magnesium carbonate hydrate; polyacrylate dispersion (30 per cent); titanium dioxide; triethyl citrate; aspartame; hyprolose; macrogol 6000; magnesium stearate; methacrylic acid - ethyl acrylate copolymer (1:1); hypromellose; crospovidone; citric acid; iron oxide red; glyceryl monostearate; iron oxide yellow; purified water; mannitol; polysorbate 80; microcrystalline cellulose; flavour; xylitol; calcium hydrogen phosphate - adults:,1.healing and long-term management of reflux oesophagitis.,2.healing and long-term management for patients with duodenal ulcer.,3.healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.,4.lansoprazole is also effective in patients with benign peptic lesions that do not respond to h2-receptor antagonists.,5.eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics (see clinical trials).,6.relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia.,paediatric patients 6 to 17 years of age.,1.treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis.,2.healing of erosive oesophagitis.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - lansoprazole, quantity: 15 mg - tablet, orally disintegrating - excipient ingredients: macrogol 6000; magnesium carbonate hydrate; purified water; hypromellose; polyacrylate dispersion (30 per cent); microcrystalline cellulose; triethyl citrate; iron oxide red; polysorbate 80; glyceryl monostearate; citric acid; titanium dioxide; purified talc; hyprolose; iron oxide yellow; methacrylic acid - ethyl acrylate copolymer (1:1); crospovidone; magnesium stearate; mannitol; aspartame; xylitol; calcium hydrogen phosphate; flavour - adults:,1.healing and long-term management of reflux oesophagitis.,2.healing and long-term management for patients with duodenal ulcer.,3.healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence.,4.lansoprazole is also effective in patients with benign peptic lesions that do not respond to h2-receptor antagonists.,5.eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics (see clinical trials).,6.relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia.,paediatric patients 6 to 17 years of age.,1.treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis.,2.healing of erosive oesophagitis.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - lansoprazole, quantity: 15 mg - tablet, orally disintegrating - 15 mg - excipient ingredients: iron oxide yellow; polysorbate 80; purified talc; microcrystalline cellulose; titanium dioxide; lactose monohydrate; aspartame; hyprolose; macrogol 8000; iron oxide red; magnesium carbonate hydrate; magnesium stearate; crospovidone; mannitol; glyceryl monostearate; hypromellose; triethyl citrate; citric acid; polyacrylate dispersion (30 per cent); purified water; methacrylic acid copolymer; sodium lauryl sulfate; flavour - adults 1. healing and long-term management of reflux oesophagitis. 2. healing and long-term management for patients with duodenal ulcer. 3. healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. 4. lansoprazole is also effective in patients with benign peptic lesions that do not respond to h2-receptor antagonists. 5. eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics (see clinical trials). 6. relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia. paediatric patients 6 to 17 years of age. 1. treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis. 2. healing of erosive oesophagitis.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

australian nuclear science and technology organisation t/a ansto - sodium iodide(131i), quantity: 1201 mbq - oral liquid, solution - excipient ingredients: sodium bicarbonate; sodium thiosulfate pentahydrate; water for injections - .

Австралия - английский - Department of Health (Therapeutic Goods Administration)

australian nuclear science and technology organisation t/a ansto - sodium iodide(131i), quantity: 50 mbq - oral liquid, solution - excipient ingredients: sodium thiosulfate pentahydrate; water for injections; sodium bicarbonate - sodium iodide (131i) solution bp (for therapy) is indicated in the treatment of hyperthyroidism's and the detection and ablation of residual functioning thyroid tissue in differentiated thyroid carcinoma